Ultragenyx Pharmaceutical Inc.
Every calculator, already run for RARE
Open the full toolkit →You have the numbers on RARE. Get the argument.
A written report on which of these readings actually decide the outcome for Ultragenyx Pharmaceutical Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
20 analysts covering RAREAnalyst Price Target Disagreement for Ultragenyx Pharmaceutical Inc.
Wall Street's bull case implies +180% from the current price; the bear case implies +12%. A 168% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for RARE
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacuma…
RARE — frequently asked
Is RARE a buy right now?
Wall Street's consensus rating on Ultragenyx Pharmaceutical Inc. is Buy across 20 analysts, with a mean price target of $27.00 (+89% vs. the current $14.30). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is RARE's next earnings date?
Ultragenyx Pharmaceutical Inc. is next scheduled to report earnings around Nov 3, 2026. A full RARE research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Ultragenyx Pharmaceutical Inc.?
Analysts covering Ultragenyx Pharmaceutical Inc. (RARE) range from a bear-case target of $16.00 to a bull-case high of $40.00, with a mean consensus target of $27.00 across 19 analysts. The spread of $24.00 (168% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Ultragenyx Pharmaceutical Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Ultragenyx Pharmaceutical Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full RARE research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Ultragenyx Pharmaceutical Inc., in minutes. 3 free reports included with every account — no credit card required.